

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA PIONEER PHARMA HOLDINGS LIMITED

中国先锋医药控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 01345)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 28 APRIL 2017

At the annual general meeting (the “AGM”) of China Pioneer Pharma Holdings Limited (the “Company”) held on 28 April 2017, voting on all the proposed resolutions as set out in the notice of the AGM dated 23 March 2017 was taken by poll.

As at the date of the AGM, the total number of issued shares of the Company was 1,333,334,000 shares, which was the total number of shares entitling the holders to attend and vote on the resolutions proposed at the AGM. There were no restrictions on any shareholders of the Company casting votes on any of the proposed resolutions at the AGM.

The Company’s Hong Kong branch share registrar, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the AGM for the purpose of vote-taking. The poll results in respect of the respective resolutions proposed at the AGM were as follows:

ORDINARY RESOLUTIONS		Number of Votes (%)	
		For	Against
1.	To receive and adopt the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors and auditor of the Company for the year ended 31 December 2016.	987,554,645 99.61%	3,840,000 0.39%
2.	To declare a final dividend for the year ended 31 December 2016.	991,394,645 100%	0 0%

ORDINARY RESOLUTIONS		Number of Votes (%)	
		For	Against
3.	To re-elect Mr. Wu Mijia as a non-executive director of the Company.	985,342,983 99.39%	6,051,662 0.61%
4.	To re-elect Mr. Wang Yinping as a non-executive director of the Company.	987,470,653 99.60%	3,923,992 0.40%
5.	To re-elect Mr. Wong Chi Hung, Stanley as an independent non-executive director of the Company.	985,342,983 99.39%	6,051,662 0.61%
6.	To authorise the board of directors of the Company to fix the remuneration of the directors of the Company.	987,554,645 99.61%	3,840,000 0.39%
7.	To re-appoint Deloitte Touche Tohmatsu as auditor of the Company and authorise the board of directors of the Company to fix its remuneration.	987,554,645 99.61%	3,840,000 0.39%
8.	To give a general mandate to the directors of the Company to allot, issue and deal with additional shares not exceeding 20% of the number of issued shares of the Company as at the date of this resolution.	936,451,008 94.46%	54,943,637 5.54%
9.	To give a general mandate to the directors of the Company to repurchase shares not exceeding 10% of the number of issued shares of the Company as at the date of this resolution.	987,554,645 99.61%	3,840,000 0.39%
10.	To extend the authority given to the directors of the Company pursuant to ordinary resolution no. 8 to issue shares by adding the number of shares repurchased under ordinary resolution no. 9.	936,431,678 94.46%	54,962,967 5.54%

As more than 50% of votes were cast in favour of each of the resolutions, all of the above ordinary resolutions were approved by the shareholders of the Company.

FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2016

The Company will pay the final dividend of RMB0.103 per share of the Company for the year ended 31 December 2016 (the “Dividend”) to shareholders whose names appear on the register of members of the Company on Monday, 8 May 2017. The dividend warrants will be posted by ordinary mail to shareholders of the Company who are entitled to receive the Dividend at their own risk on Monday, 15 May 2017.

By order of the Board
China Pioneer Pharma Holdings Limited
Li Xinzhou
Chairman

Hong Kong, 28 April 2017

As at the date of this announcement, the directors of the Company are Mr. LI Xinzhou and Mr. ZHU Mengjun as executive directors, Mr. WANG Yinping and Mr. WU Mijia as non-executive directors and Mr. XU Zhonghai, Mr. LAI Chanshu and Mr. WONG Chi Hung, Stanley as independent non-executive directors.